Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus

Amneris Luque, S. Hulse, D. Wang, U. Shahzad, E. Tanzman, S. Antenozzi, B. Smith

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

OBJECTIVE. To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF). METHODS. Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP. SETTING. University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center. PARTICIPANTS. Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004. RESULTS. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure. CONCLUSION. Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

Original languageEnglish (US)
Pages (from-to)695-701
Number of pages7
JournalInfection Control and Hospital Epidemiology
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Lamivudine
Occupational Exposure
HIV
Tenofovir
Zidovudine
Nausea
Student Health Services
Indinavir
Occupational Health
Acquired Immunodeficiency Syndrome
Multivariate Analysis
Delivery of Health Care

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. / Luque, Amneris; Hulse, S.; Wang, D.; Shahzad, U.; Tanzman, E.; Antenozzi, S.; Smith, B.

In: Infection Control and Hospital Epidemiology, Vol. 28, No. 6, 01.06.2007, p. 695-701.

Research output: Contribution to journalArticle

@article{3f84810e9cbe4037b15918a92f31855f,
title = "Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus",
abstract = "OBJECTIVE. To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF). METHODS. Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP. SETTING. University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center. PARTICIPANTS. Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004. RESULTS. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure. CONCLUSION. Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.",
author = "Amneris Luque and S. Hulse and D. Wang and U. Shahzad and E. Tanzman and S. Antenozzi and B. Smith",
year = "2007",
month = "6",
day = "1",
doi = "10.1086/518349",
language = "English (US)",
volume = "28",
pages = "695--701",
journal = "Infection Control and Hospital Epidemiology",
issn = "0899-823X",
publisher = "University of Chicago Press",
number = "6",

}

TY - JOUR

T1 - Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus

AU - Luque, Amneris

AU - Hulse, S.

AU - Wang, D.

AU - Shahzad, U.

AU - Tanzman, E.

AU - Antenozzi, S.

AU - Smith, B.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - OBJECTIVE. To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF). METHODS. Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP. SETTING. University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center. PARTICIPANTS. Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004. RESULTS. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure. CONCLUSION. Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

AB - OBJECTIVE. To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF). METHODS. Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP. SETTING. University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center. PARTICIPANTS. Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004. RESULTS. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure. CONCLUSION. Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

UR - http://www.scopus.com/inward/record.url?scp=34250700917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250700917&partnerID=8YFLogxK

U2 - 10.1086/518349

DO - 10.1086/518349

M3 - Article

C2 - 17520543

AN - SCOPUS:34250700917

VL - 28

SP - 695

EP - 701

JO - Infection Control and Hospital Epidemiology

JF - Infection Control and Hospital Epidemiology

SN - 0899-823X

IS - 6

ER -